Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Transcatheter aortic valve replacement and mitral edge-to-edge repair. Main billing specialties: interventional cardiology and cardiac surgery.
Medicare fee-for-service structural heart (TAVR, TEER) cases in the 49 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (219 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 238 | 5,995+3.6%/yr | +3.6%/yr | 1.50.9× | 0% | 8,310 in 2030+5.6%/yr |
| Florida | 217 | 4,689+3.4%/yr | +3.4%/yr | 1.71.1× | 0% | 6,380 in 2030+5.3%/yr |
| New York | 150 | 4,552+1.5%/yr | +1.5%/yr | 2.11.3× | 0% | 6,000 in 2030+4.7%/yr |
| Texas | 191 | 3,813+6.2%/yr | +6.2%/yr | 1.50.9× | 0% | 6,400 in 2030+9%/yr |
| Pennsylvania | 158 | 2,820+2.5%/yr | +2.5%/yr | 1.71.0× | 0% | 3,580 in 2030+4%/yr |
| Illinois | 119 | 2,664+7.3%/yr | +7.3%/yr | 1.71.0× | 0% | 3,910 in 2030+6.6%/yr |
| Ohio | 99 | 2,063+1.4%/yr | +1.4%/yr | 1.50.9× | 0% | 2,940 in 2030+6.1%/yr |
| Massachusetts | 66 | 2,037+3.4%/yr | +3.4%/yr | 1.91.2× | 0% | 3,210 in 2030+7.9%/yr |
| Virginia | 70 | 2,001+4.7%/yr | +4.7%/yr | 1.71.0× | 0% | 2,460 in 2030+3.5%/yr |
| Tennessee | 67 | 1,854+4.5%/yr | +4.5%/yr | 2.21.3× | 0% | 2,680 in 2030+6.3%/yr |
| Georgia | 72 | 1,794+2.7%/yr | +2.7%/yr | 1.71.0× | 0% | 2,890 in 2030+8.3%/yr |
| Washington | 65 | 1,756+5.4%/yr | +5.4%/yr | 1.91.2× | 0% | 2,430 in 2030+5.5%/yr |
| Minnesota | 87 | 1,733+5.1%/yr | +5.1%/yr | 3.11.9× | 0% | 2,780 in 2030+8.2%/yr |
| Michigan | 94 | 1,656+3%/yr | +3%/yr | 1.61.0× | 0% | 2,670 in 2030+8.3%/yr |
| New Jersey | 71 | 1,653+2.7%/yr | +2.7%/yr | 1.40.8× | 0% | 2,140 in 2030+4.4%/yr |
| Arizona | 74 | 1,643+5.5%/yr | +5.5%/yr | 1.91.1× | 0% | 2,270 in 2030+5.5%/yr |
| Indiana | 68 | 1,501+7.4%/yr | +7.4%/yr | 1.81.1× | 0% | 2,410 in 2030+8.2%/yr |
| North Carolina | 75 | 1,460−1.4%/yr | −1.4%/yr | 1.20.7× | 0% | 2,070 in 2030+6%/yr |
| Wisconsin | 64 | 1,422+6.9%/yr | +6.9%/yr | 2.11.3× | 0% | 1,970 in 2030+5.6%/yr |
| South Carolina | 56 | 1,406+10%/yr | +10%/yr | 1.81.1× | 0% | 2,380 in 2030+9.2%/yr |
| Missouri | 69 | 1,246+3.7%/yr | +3.7%/yr | 1.71.0× | 0% | 1,610 in 2030+4.4%/yr |
| Maryland | 45 | 1,095+6.5%/yr | +6.5%/yr | 1.10.7× | 0% | 1,750 in 2030+8.1%/yr |
| Kansas | 30 | 866+1.2%/yr | +1.2%/yr | 1.91.2× | 0% | 1,110 in 2030+4.2%/yr |
| Oregon | 39 | 802+2.6%/yr | +2.6%/yr | 1.61.0× | 0% | 1,140 in 2030+6%/yr |
| Colorado | 33 | 787+4.2%/yr | +4.2%/yr | 1.30.8× | 0% | 1,130 in 2030+6.3%/yr |
| Oklahoma | 38 | 772+1.6%/yr | +1.6%/yr | 1.40.8× | 0% | 1,030 in 2030+4.9%/yr |
| Alabama | 44 | 739−2.6%/yr | −2.6%/yr | 1.40.8× | 0% | 660 in 2030−1.9%/yr |
| Louisiana | 50 | 724+2.7%/yr | +2.7%/yr | 1.50.9× | 0% | 940 in 2030+4.5%/yr |
| Kentucky | 40 | 718+4.9%/yr | +4.9%/yr | 1.30.8× | 0% | 940 in 2030+4.5%/yr |
| Iowa | 30 | 618+2.5%/yr | +2.5%/yr | 1.20.7× | 0% | 640 in 2030+0.7%/yr |
| New Hampshire | 24 | 582+6.7%/yr | +6.7%/yr | 2.31.4× | 0% | 1,340 in 2030+15%/yr |
| Connecticut | 32 | 563−1.1%/yr | −1.1%/yr | 1.40.9× | 0% | 1,000 in 2030+10%/yr |
| Arkansas | 31 | 553+0.7%/yr | +0.7%/yr | 1.30.8× | 0% | 420 in 2030−4.4%/yr |
| Nevada | 30 | 487+4.8%/yr | +4.8%/yr | 1.40.9× | 0% | 610 in 2030+3.7%/yr |
| Nebraska | 26 | 451+5.5%/yr | +5.5%/yr | 1.50.9× | 0% | 490 in 2030+1.4%/yr |
| Mississippi | 30 | 446+8%/yr | +8%/yr | 1.00.6× | 0% | 590 in 2030+4.9%/yr |
| Utah | 21 | 422−1.7%/yr | −1.7%/yr | 1.61.0× | 0% | 410 in 2030−0.3%/yr |
| South Dakota | 11 | 391+14%/yr | +14%/yr | 2.71.6× | 0% | 780 in 2030+12%/yr |
| Montana | 15 | 357+1.6%/yr | +1.6%/yr | 1.71.0× | 0% | 480 in 2030+5.2%/yr |
| North Dakota | 13 | 293+12%/yr | +12%/yr | 2.61.6× | 0% | 520 in 2030+10%/yr |
| Delaware | 16 | 290+19%/yr | +19%/yr | 1.50.9× | 0% | 520 in 2030+10%/yr |
| District of Columbia | 8 | 271−1.1%/yr | −1.1%/yr | 3.82.3× | 0% | 310 in 2030+2.3%/yr |
| West Virginia | 12 | 269+1.5%/yr | +1.5%/yr | 1.10.7× | 0% | 460 in 2030+9.3%/yr |
| Rhode Island | 9 | 263+10%/yr | +10%/yr | 2.31.4× | 0% | 340 in 2030+4.3%/yr |
| Idaho | 17 | 257+2.2%/yr | +2.2%/yr | 1.10.6× | 0% | 530 in 2030+13%/yr |
| Maine | 15 | 221+2.2%/yr | +2.2%/yr | 1.10.7× | 0% | 460 in 2030+13%/yr |
| New Mexico | 9 | 207+20%/yr | +20%/yr | 0.80.5× | 0% | 260 in 2030+4%/yr |
| Vermont | 6 | 189+4.2%/yr | +4.2%/yr | 1.50.9× | 0% | 300 in 2030+7.8%/yr |
| Alaska | 5 | 100+16%/yr | +16%/yr | 0.80.5× | 0% | 190 in 2030+11%/yr |
Professional codes (what the surgeon bills): CPT 33361, 33362, 33363, 33364, 33365, 33366, 33418, 33419; the hospital bills MS-DRG 266, 267.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 680 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 5 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Edwards Lifesciences | 319 |
| Medtronic | 230 |
| Abbott | 96 |
| Boston Scientific | 29 |
| Jenavalve Technology | 6 |
Product codes: DYE (replacement heart-valve), NKM (mitral valve repair devices), NPT (aortic valve, prosthesis, percutaneously delivered). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 23% of the cases CMS names in California; 126 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Coronary intervention (PCI) | 5,056 | 218,309−6.5%/yr | −6.5%/yr | 236,300 in 2030+1.3%/yr |
| Mechanical circulatory support | 56 | 17,228−4.4%/yr | −4.4%/yr | 19,300 in 2030+1.9%/yr |
| PFO & septal closure | 10 | 1,097+2.2%/yr | +2.2%/yr | 1,130 in 2030+0.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 8 companies reported engagement with surgeons in the covered states worth $33M in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 52 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.